Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.

J Infus Nurs

New York Cancer & Blood Specialists, East Setauket, New York (Mr Calcanes and Dr Vacirca). George Calcanes, BS, RN, is chief clinical officer at New York Cancer & Blood Specialists, where he manages an extensive oncology practice with infusion suites for outpatient chemotherapy. He institutes new chemotherapy regimens, clinics, and services for a large patient population, coordinating between clinical staff and pharmaceutical companies for optimal patient care. Jeffrey L. Vacirca, MD, FACP, is chief executive officer, managing partner, and director of clinical research at New York Cancer & Blood Specialists. He is also medical director for the International Oncology Network in Frisco, Texas; president of Community Oncology Alliance; and president of the National Translational Research Group in East Setauket, NY. His specialties include breast, prostate, and complicated cancers.

Published: December 2019

HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328855	PMC
http://dx.doi.org/10.1097/NAN.0000000000000341	DOI Listing

Publication Analysis

Top Keywords

safety profile

patients cancer

htx-019 administered

intravenous infusion

cancer retrospective

retrospective analysis

analysis htx-019

favorable safety

htx-019

safety

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!